恩度联合化疗治疗消化系统晚期癌症的临床研究进展  

Advances in the research of Endostar combined with chemotherapy in treatment of gastrointestinal cancer

作　　者：张世军[1] 姜秋颖[1] 

机构地区：[1]哈尔滨医科大学附属第二医院肿瘤内科,黑龙江哈尔滨150086

出　　处：《现代肿瘤医学》2017年第13期2178-2182,共5页Journal of Modern Oncology

摘　　要：异常血管生成是各种实体瘤生长、转移共同的病理过程,抗血管生成已成为目前治疗肿瘤的重要途径。重组人血管内皮抑制素恩度是一种多靶点抗血管生成药物,试验表明其与传统化疗药物联合应用可以产生协同增效的作用,现已获得中国食品药品监督管理局批准将化疗药物联合恩度用于治疗晚期非小细胞肺癌。近年来,一些临床研究发现恩度与传统化疗药物联合在消化道恶性肿瘤的治疗中表现出稳定的有效性和安全性,可能具有良好的应用前景。本文从有效性和安全性两个方面概述恩度联合传统化疗药物治疗消化系统常见恶性肿瘤的临床研究进展,以期为后续研究和临床实践提供思路和依据。Angiogenesis takes critical responsibility for the survival and metastasis of all sorts of solid tumors. To overcome cancers, blocking this pathological process has been a critical modality. Rh - endostatin（Endostar） , a multi- ple targeted antiangiogenesis drug, which enhances the efficacy when combined with chemotherapy in the treatment of advanced non- small cell lung cancer（NSCLC） , has been approved by the Chinese Food and Drug Administration （CFDA） for the treatment of advanced NSCLC. In recent years, some clinical studies have suggested that Endostar combined with chemotherapy might be a effective and safe way to treat gastrointestinal cancers, and deserving further promotion to clinical application. To serve the further research and clinical practice, herein, we reviewed the advances in clinical research on the efficacy and safety of Endostar combined with chemotherapy in the treatment of advanced gastrointestinal cancer.

关 键 词：重组人血管内皮抑制素 化疗 消化道恶性肿瘤 有效性 安全性 

分 类 号：R735[医药卫生—肿瘤]